NCT03634085View on ClinicalTrials.gov

Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

August 13, 2018

Study Completion Date

August 28, 2018

Conditions
Healthy
Interventions
DRUG

BDM-2 in Bottle (50 mg - 3600 mg); oral suspension

BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors

Collaborators (1)

Venn Life Sciences
All Listed Sponsors
collaborator

Venn Life Sciences

OTHER

lead

Hivih

INDUSTRY

NCT03634085 - Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects. | Biotech Hunter | Biotech Hunter